Advancing Therapies for Patients

Find a clinical trial

page image


shadow image


Find a clinical trial

06 December 2013


NASHVILLE, TN, December 6, 2013 Sarah Cannon Research Institute (SCRI) announced today that the American Society for Hematology (ASH) has selected 37 abstracts authored by SCRI investigators to be presented at the 2013 ASH Annual Meeting and Exposition. Hosted in New Orleans from December 7-10, the meeting brings together more than 20,000 hematologists and other oncology professionals from a broad range of specialties to discuss the latest breakthroughs in blood cancer research and treatment.

The presentations from SCRI include 12 abstracts in oral sessions and 25 posters representing in-progress trials. Investigators from Sarah Cannon Blood Cancer Network – which along with SCRI, are a part of the Sarah Cannon enterprise – will present 10 additional abstracts at the conference. All represented studies are focused on the efficacy of targeted therapies for various types of leukemia, lymphoma, and other blood disorders. A complete schedule of the presentations is available at

“SCRI’s scientific representation at this annual meeting has doubled over the last year, demonstrating our physician leaders’ expertise and collaborative approach to advancing novel therapies for blood cancers,” said SCRI CMO Howard A. Burris III, MD. “As a leading cancer network of excellence, we are committed to raising the standard of care for cancer patients in the communities that we serve, and our research efforts are helping us to accomplish these goals more rapidly and effectively.”

In addition to our poster and oral sessions, two of our principal investigators have been selected to lead symposium sessions. SCRI’s Director of Hematologic Malignancies Research, Ian W. Flinn, MD, PhD, will present updates in chronic lymphocytic leukemia and other B-cell malignancies. Sarah Cannon’s Chief of Hematology, Charles F. LeMaistre, MD, who is the current President of the American Society for Blood and Marrow Transplantation, will discuss transplantation for adults with acute lymphoblastic leukemia.

“Sarah Cannon is not only known for its research excellence, but also for the way it is transforming cancer care, particularly in the treatment of blood cancers,” said LeMaistre. “Through our expert clinicians within the Sarah Cannon Blood Cancer Network, we are helping patients achieve improved outcomes from blood and marrow transplantation as well as through other advanced treatment options.”

Affiliated clinicians participating in the Sarah Cannon Blood Cancer Network will also be presenting their findings during the 2013 ASH Annual Meeting and their scheduled presentations are listed in the ASH section of

About Sarah Cannon Research Institute

Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the world’s leading clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 700 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors and strategic investigator sites. For more information, please visit

About The Sarah Cannon Blood Cancer Network

 The Sarah Cannon Blood Cancer Network is one of the largest providers of blood cancer care including blood and marrow transplantation (BMT) across the United States and United Kingdom. Its network conducts over 800 transplants annually and has treated more than 9,500 patients since the inception of our first program. Through its commitment to the highest level of quality standards, infrastructure, training and research, the Sarah Cannon Blood Cancer Network provides an unparalleled experience for patients seeking treatment. For more information about the Blood Cancer Network and Sarah Cannon’s full suite of oncology services, please visit:

<< Back to News

Latest Videos

watch the latest videos.

Learn more


news from the industry.

Read more

hero1 image
Sarah Cannon Research UK NHS Ventures
University College London Hospitals